Medicare finalizes coverage for Renalytix's kidneyIntelX.dkd at $950/test effective Aug 1, 2024

Renalytix plc

Medicare issued final Local Coverage Determination (LCD) for kidneyIntelX.dkd; effective dates of service on/after August 1, 2024.
Established Medicare price is $950 per test; distinct CPT codes published in CMS 2024 Clinical Lab Fee Schedule.
Coverage applies to patients with Type 2 diabetes and Stage 1-3b Chronic Kidney Disease per FDA label.
LCD issued by National Government Services (NGS), a Medicare Administrative Contractor for the company's NYC lab.
CEO expects coverage to prompt additional major insurance decisions and accelerate test adoption.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.